Hepatitis B incidence falls in the Western Pacific as mortality moves the other way
Across the Western Pacific Region, hepatitis B is not following a single, tidy trajectory. Modelled estimates from 34 countries and areas show a steady decline in regional prevalence and chronic incidence between 2015 and 2024, yet crude mortality increased over the same period. The gap between fewer new infections and more deaths is the central signal in this analysis, and it sharpens a long-standing concern: transmission control does not automatically translate into reduced fatal disease.
Regional HBV prevalence fell from 5.28% in 2015 to 4.58% in 2024, while chronic incidence dropped from 6.32 to 3.16 per 100,000 population. On the surface, those shifts suggest real progress in prevention, likely reflecting the cumulative effects of vaccination, safer blood supply practices, and broader public health efforts aimed at curbing vertical and horizontal transmission. The biological logic is straightforward. If fewer people acquire HBV early in life or through ongoing exposure, the pool of chronically infected individuals should shrink over time. Yet chronic hepatitis B is a slow-moving disease, and the consequences of decades of infection do not disappear when incidence begins to fall.
Mortality climbed from 22.88 to 24.70 per 100,000 population. That increase matters because it means the region is still carrying the legacy of earlier infection, cirrhosis, hepatocellular carcinoma, and delayed diagnosis. In practical terms, a lower infection rate can coexist with a worsening death toll when the existing infected population is aging into advanced liver disease, antiviral treatment access remains uneven, or care begins too late to alter long-term outcomes.
Under-five prevalence remains stuck above the WHO elimination threshold
One of the clearest markers of stalled progress was the under-five prevalence estimate, which plateaued at about 0.28% to 0.29% from 2019 onward. The WHO 2030 target is 0.1% or less, and the region remains above that benchmark. For a disease in which perinatal and early-childhood transmission have outsized importance, this stubborn plateau is clinically consequential. It suggests that prevention at birth is still incomplete in many settings, whether because of gaps in maternal screening, timely birth-dose vaccination, or the logistics of reaching infants immediately after delivery.
A plateau in young children is not just a surveillance artifact. It signals ongoing transmission opportunities at the very point where elimination strategies are supposed to be most effective. If infants continue to acquire HBV early, the downstream burden of chronic infection will persist for decades, feeding the future pool of cirrhosis and liver cancer even if adult incidence continues to recede.
The analysis also found that 55.9% of countries and areas had declining chronic incidence alongside increasing mortality. That split is hard to ignore. It shows how elimination metrics can point in opposite directions when they are treated as interchangeable. Transmission curves and mortality curves answer different clinical questions, and they move on different timetables.
Country-level heterogeneity complicates regional progress
The study used standardised modelled estimates from the Center for Disease Analysis Foundation and applied log-linear regression to derive estimated annual percentage change. The resulting picture was not one of a uniform regional decline, but of considerable country-level variation layered beneath the aggregate trend. Evidence for systematic differences across analytical subregions was limited, yet the authors still found enough heterogeneity to argue against treating the Western Pacific as a single epidemiologic unit.
That heterogeneity has direct implications for elimination strategy. Some countries may be moving closer to control through vaccination and prevention, while others remain caught in a cycle of persistent chronic infection, late diagnosis, and insufficient treatment coverage. Regional averages can conceal these fractures. A country with falling incidence may still have rising deaths if the infected population is older, surveillance is weak, or treatment scale-up has lagged behind prevention gains.
The modest correlation between incidence and mortality trends, with r = 0.39 and a 95% CI of 0.06-0.64, reinforces the point. The relationship exists, but it is not strong enough to assume that reducing transmission will automatically lower deaths in lockstep. HBV elimination demands parallel gains in both prevention and clinical management: vaccination, case finding, staging, antiviral therapy, and liver cancer surveillance. Without that second track, mortality can remain stubborn even as incidence falls.
Why falling transmission has not yet translated into falling deaths
The biology of chronic hepatitis B helps explain the discordance. HBV often smolders for years before cirrhosis or cancer appears, so mortality reflects infections acquired long before the latest prevention gains. In addition, many people with chronic HBV remain undiagnosed until advanced liver disease is already present. Once cirrhosis is established, the clinical course becomes more difficult to reverse, and the risk of hepatocellular carcinoma remains substantial even with treatment.
Treatment access is the other likely bottleneck. Antiviral therapy can suppress viral replication and reduce complications, but population-level mortality falls only when infected people are identified early and linked to care consistently. If diagnostic coverage is uneven, if antiviral initiation is delayed, or if follow-up after diagnosis is incomplete, mortality will lag behind incidence trends. The data in this analysis are compatible with that reality, although the modelled design cannot isolate which countries are most affected by each mechanism.
The study’s sensitivity analyses strengthened confidence in the broad pattern by testing influential observations, shared model trajectories, non-linearity, and alternative country classification. Even with those checks, the same broad asymmetry remained: transmission is receding, but death is not receding at the same pace. That asymmetry should shape how elimination progress is judged.
Elimination monitoring must separate transmission from mortality
This analysis argues for a more disciplined approach to HBV elimination monitoring in the Western Pacific Region. Incidence and mortality should not be collapsed into a single notion of progress. A program can reduce new infections and still fail on survival if it does not reach people who already carry chronic disease. For clinicians and policymakers, the practical consequence is clear: vaccination metrics alone are not enough, and mortality data must be tracked with equal seriousness.
WHO-supported efforts in the region need to account for the fact that many countries are now managing two epidemics at once: fewer new infections among children and adults, and a large reservoir of chronic disease accumulated over earlier decades. The first problem is a prevention challenge. The second is a treatment and long-term surveillance challenge. They require different tools, different budgets, and different timetables.
The modelled nature of the estimates also places boundaries on interpretation. Ecological data cannot substitute for patient-level outcomes, and regional comparisons cannot capture every local programmatic change. Even so, the message is direct: reduced HBV transmission has not yet delivered equivalent mortality relief across much of the Western Pacific. Any elimination strategy that does not treat those outcomes as separate endpoints risks missing the disease burden that still sits in plain view.